BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia.
B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1)
acute myeloid leukemia (AML)
hematopoietic progenitor cell antigen cluster of differentiation 34 (CD34)
meningioma 1 (MN1)
myelodysplastic syndrome (MDS)
myeloid cell leukemia 1 (MCL1)
tumor suppressor protein 53 (TP53)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Feb 2021
02 Feb 2021
Historique:
received:
17
12
2020
revised:
21
01
2021
accepted:
28
01
2021
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
6
2
2021
Statut:
epublish
Résumé
Prognosis for acute myeloid leukemia (AML) patients is poor, particularly in The BMI1 inhibitor PTC596, MCL1 inhibitor S63845, and MEK inhibitor trametinib, as well as the p53 activator APR-246 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells. AML cells represented all major morphologic and molecular subtypes including AML cell lines were variably susceptible to PTC596 and to combination treatments with PTC596 and MCL1 inhibitor S63845, MEK inhibitor trametinib, or The combination of PTC596 and S63845 may be an effective treatment in CD34+ adverse risk AML with elevated
Identifiants
pubmed: 33540760
pii: cancers13030581
doi: 10.3390/cancers13030581
pmc: PMC7867282
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 310030_127509
Références
Cancers (Basel). 2018 May 31;10(6):
pubmed: 29857559
J Clin Oncol. 2009 Jul 1;27(19):3198-204
pubmed: 19451432
Genes Dis. 2015 Sep;2(3):225-239
pubmed: 26448339
Cell Stem Cell. 2020 Aug 6;27(2):238-253.e6
pubmed: 32697949
Br J Haematol. 2016 Jul;174(1):117-26
pubmed: 26991755
Leukemia. 2007 May;21(5):1116-22
pubmed: 17377594
Blood Cancer J. 2017 Feb 17;7(2):e527
pubmed: 28211885
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Haematologica. 2018 Nov;103(11):1862-1872
pubmed: 29976747
Clin Pharmacol Drug Dev. 2021 Jan 13;:
pubmed: 33440067
J Clin Oncol. 2012 Oct 10;30(29):3633-9
pubmed: 22965953
Leukemia. 2011 Aug;25(8):1335-43
pubmed: 21527932
Cancers (Basel). 2019 Nov 12;11(11):
pubmed: 31718075
Blood. 2011 Oct 13;118(15):4188-98
pubmed: 21828125
Blood. 2006 Dec 1;108(12):3898-905
pubmed: 16912223
Hematology. 2013 Sep;18(5):277-83
pubmed: 23394438
Nat Med. 2002 Mar;8(3):282-8
pubmed: 11875500
Cancer Sci. 2015 Dec;106(12):1705-13
pubmed: 26450753
PLoS One. 2012;7(8):e43185
pubmed: 22905229
Ann Hematol. 2013 Aug;92(8):1063-9
pubmed: 23515710
Leukemia. 2010 Mar;24(3):601-12
pubmed: 20072157
Clin Cancer Res. 2016 Feb 1;22(3):746-56
pubmed: 26408402
Cancers (Basel). 2017 Dec 16;9(12):
pubmed: 29258181
Biomark Cancer. 2016 May 05;8:65-75
pubmed: 27168727
Biomark Res. 2016 Dec 16;4:23
pubmed: 28018598
Leuk Res. 2020 Feb;89:106296
pubmed: 31927137
Blood Rev. 2018 Nov;32(6):508-519
pubmed: 29728319
Oncotarget. 2018 Jun 19;9(47):28547-28560
pubmed: 29983879
J Cell Biochem. 2011 Oct;112(10):2729-41
pubmed: 21678481
Leukemia. 1998 Nov;12(11):1685-95
pubmed: 9823942